RU2016118775A - Prionic Acid Controlled Release Pharmaceutical Composition - Google Patents

Prionic Acid Controlled Release Pharmaceutical Composition Download PDF

Info

Publication number
RU2016118775A
RU2016118775A RU2016118775A RU2016118775A RU2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A RU 2016118775 A RU2016118775 A RU 2016118775A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
controlled release
wax
cellulose
composition according
Prior art date
Application number
RU2016118775A
Other languages
Russian (ru)
Other versions
RU2669920C2 (en
Inventor
Се-Йеон КАНГ
БО-Рам ЧАЕ
Еун-Дзин СУНГ
Дзонг-Хиун ЛИ
Сех-Хион СОНГ
Се-Ил СОН
Хонг-Воо ЛИ
Original Assignee
Дае Вон Фармасьютикал Ко.,Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дае Вон Фармасьютикал Ко.,Лтд. filed Critical Дае Вон Фармасьютикал Ко.,Лтд.
Publication of RU2016118775A publication Critical patent/RU2016118775A/en
Application granted granted Critical
Publication of RU2669920C2 publication Critical patent/RU2669920C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (4)

1. Фармацевтическая композиция, содержащая пелубипрофен и полимер контролируемого высвобождения, где полимером контролируемого высвобождения является водонерастворимый полимер.1. A pharmaceutical composition comprising pelubiprofen and a controlled release polymer, wherein the controlled release polymer is a water-insoluble polymer. 2. Фармацевтическая композиция по п. 1, отличающаяся тем, что композиция растворяется менее чем на 30% в гастроинтестинальной области (растворяющая жидкость с pH 1,2) в течении 2 часов.2. The pharmaceutical composition according to claim 1, characterized in that the composition is dissolved by less than 30% in the gastrointestinal region (dissolving liquid with a pH of 1.2) within 2 hours. 3. Фармацевтическая композиция по п. 2, отличающаяся тем, что композиция растворяется более чем на 50% в области тонкого кишечника(растворяющая жидкость с pH 6,8) в течение 2 часов.3. The pharmaceutical composition according to claim 2, characterized in that the composition is dissolved by more than 50% in the small intestine (dissolving liquid with a pH of 6.8) within 2 hours. 4. Фармацевтическая композиция по п. 2 или 3, отличающаяся тем, что водонерастворимый полимер выбран из группы, состоящей из карбомера, производных целлюлозы, выбраных из карбоксиметилцеллюлозы кальция, целлюлозы ацетата фталата, метилцеллюлозы, гидроксипропил метилцеллюлозы фталата, воска выбранного из микрокристаллического воска, белого воска, карнаубского воска, спермацета и эмульгирующего воска, метакрилатного сополимера, этилцеллюлозы, поливинилацетата, Коллидона SR и их смесей.4. The pharmaceutical composition according to claim 2 or 3, characterized in that the water-insoluble polymer is selected from the group consisting of carbomer, cellulose derivatives selected from calcium carboxymethyl cellulose, cellulose acetate phthalate, methyl cellulose, hydroxypropyl methyl cellulose phthalate, wax selected from microcrystalline wax, white wax, carnauba wax, spermaceti and emulsifying wax, methacrylate copolymer, ethyl cellulose, polyvinyl acetate, Collidon SR and mixtures thereof.
RU2016118775A 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid RU2669920C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020130124001A KR101561345B1 (en) 2013-10-17 2013-10-17 Controlled-release pharmaceutical composition of propionic acid derivatives
KR10-2013-0124001 2013-10-17
PCT/KR2014/009634 WO2015056956A1 (en) 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid

Publications (2)

Publication Number Publication Date
RU2016118775A true RU2016118775A (en) 2017-11-22
RU2669920C2 RU2669920C2 (en) 2018-10-17

Family

ID=52828338

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016118775A RU2669920C2 (en) 2013-10-17 2014-10-14 Controlled release pharmaceutical composition based on propionic acid

Country Status (4)

Country Link
KR (1) KR101561345B1 (en)
CN (1) CN105705166B (en)
RU (1) RU2669920C2 (en)
WO (1) WO2015056956A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102462607B1 (en) * 2020-11-11 2022-11-03 대원제약주식회사 Pharmaceutical composition with improved stability comprising novel salt of pelubiprofen as an active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2007129169A2 (en) * 2006-05-04 2007-11-15 Pfizer Limited Cox- ii inhibitors for improving reproductive success in a female animal
JP2009543780A (en) * 2006-07-11 2009-12-10 ミューチュアル ファーマシューティカル カンパニー，インク． Controlled release formulations and kits
CN101500542A (en) * 2006-07-11 2009-08-05 共有药物有限公司 Controlled-release formulations
KR100922519B1 (en) * 2008-11-12 2009-10-20 대원제약주식회사 Pharmaceutical formulation having improved dissolution rate and stability for oral administration containing pelubiprofen
KR20100130882A (en) * 2009-06-04 2010-12-14 삼아제약 주식회사 Extended release nsaid compositions and preparing method thereof
US9066918B2 (en) * 2010-08-18 2015-06-30 Del Mar Pharmaceuticals Methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol

Also Published As

Publication number Publication date
RU2669920C2 (en) 2018-10-17
KR101561345B1 (en) 2015-10-16
CN105705166B (en) 2019-08-09
KR20150044670A (en) 2015-04-27
CN105705166A (en) 2016-06-22
WO2015056956A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
HRP20171512T1 (en) Derivatives of betulin
RU2014101227A (en) COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRICEUTIC MEDICINAL FORMS
NZ708272A (en) Pharmaceutical composition with improved bioavailability
RU2014152031A (en) COMPOSITIONS OF SOLID DOSED MEDICINAL FORMS OF THE OREXIN RECEPTOR ANTAGONIST
RU2013108256A (en) DISPERSIONS OF Razagilin Citrate
RU2014138378A (en) NANOCRYSTALLINE CELLULOSE (NCC) IN TAPE SEWING COMPOSITIONS (SC)
EA201990223A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH CONTROLLED DISSOLUTION SPEED CONTAINING Slow-Release PELLETS CONTAINING TAMSULOSINE HYDROCHLORIDE
AR065539A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE NANOPARTICLES THAT INCLUDE ENTERIC POLYMERS AND CASEINA
EA201492126A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE AND AMINO ACIDS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION
BR112017019920A2 (en) The solid tablet containing colorant
RU2012100709A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
HRP20220313T1 (en) Processes for preparing oxathiazin-like compounds
CA2797812A1 (en) Enteric tablet
RU2016143195A (en) APPLICATION OF LACTOBACILIUS RHAMNOSUS FOR STIMULATING THE RESTORATION OF INTESTINAL INTESTINAL MICROBIOTA AFTER DYSBACTERIOSIS
AR071970A1 (en) SILDENAFIL PULSATILE RELEASE COMPOSITION AND PROCESS TO PREPARE IT
RU2016118775A (en) Prionic Acid Controlled Release Pharmaceutical Composition
RU2015140119A (en) Enteric Coated Tablet
BR112015023381A2 (en) sovaprevir immediate release composition, sovaprevir 200 mg composition, sovaprevir tablet core and coated sovaprevir tablet
JP2009519313A5 (en)
RU2013130309A (en) SOLID MOLECULAR DISPERSION
RU2012151315A (en) Enteric TABLET
RU2011110756A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPO AND ENTACAPONE, OR THEIR SALT
JP2016513680A5 (en)
EA201791523A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING GRANULES WITH SLOW-DOWNSHEATING, CONTAINING TAMSULOSINE HYDROCHLORIDE
RU2014112829A (en) METHOD FOR PRODUCING MICRO CAPSULES OF AMINO ACIDS IN SODIUM ALGINATE